Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LUXTURNA safely and effectively. See full prescribing information for LUXTURNA.LUXTURNA (voretigene neparvovec-rzyl) intraocular suspension for subretinal injectionInitial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).
- generic_name
- voretigene neparvovec-rzyl
- brand_name
- diluent
- product_names
- voretigene neparvovec-rzyl, diluent
- ndc
- 71394-415, 71394-065, 71394-716, 71394-415-01, 71394-065-01, 71394-716-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en